MGC936 is a first-in-class ADAM9-targeting antibody-drug conjugate (ADC) that is comprised of a high-affinity humanized antibody site-specifically conjugated to DM21, a next-generation maytansinoid microtubule-disrupting payload, and combined with a stable peptide linker.
ADAM9 is a cell surface protein that belongs to the ADAM (a disintegrin and metalloproteinase) family of proteases, which have been implicated in cytokine and growth factor shedding and cell migration. Dysregulation of ADAM9 has been implicated in tumor progression and metastasis, as well as pathological neovascularization. It has been shown that ADAM9 is overexpressed in multiple solid tumor types (e.g., non-small cell lung cancer, gastric, pancreatic, triple-negative breast, and colorectal) and minimally expressed on normal tissue, making ADAM9 an attractive target for ADC development.
IMGC936 is being co-developed with MacroGenics and is currently in Phase 1 study.
For more information on the ongoing IMGC936 clinical trial, visit www.clinicaltrials.gov.
Visit our Publications page to access IMGC936 data presentations from past medical meetings.